Cécile R.
- Country
- France
- Department
- Service d'hématologie et d'oncologie pédiatrique
Research Overview
- Pharmacokinetics of anti-lymphocyte serum in the prevention of GvHD in children and adults receiving allogeneic hematopoietic stem cell transplantation - PHASAL-GA Study
- International Pediatric Study of Arsenic Trioxide and Tretinoin ± Gemtuzumab Ozogamicin for Acute Promyelocytic Leukemia in Children and Adolescents
- Randomized Phase 3 Trial of Venetoclax Added to Fludarabine, High‑Dose Cytarabine, and Gemtuzumab Ozogamicin in Children with Relapsed Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 86 of 135 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome, with particular focus on pediatric populations. Their research extends to novel therapeutic approaches for isolated myeloid sarcoma.
- Novel targeted therapies in AML
- Pediatric leukemia treatment optimization
- Innovative therapeutic agents
Stem Cell Transplantation
Expertise in hematopoietic stem cell transplantation (HSCT) procedures, including management of transplant-related complications such as thrombotic microangiopathy. The investigator works with both pediatric and adult populations requiring allogeneic transplantation.
- Transplant conditioning regimens
- Post-transplant complications
- Supportive care strategies
Graft-versus-Host Disease
Focus on treating steroid-refractory acute graft-versus-host disease (GvHD), with expertise in developing and evaluating novel therapeutic approaches. The investigator studies various aspects of GvHD prevention and management strategies.
- Novel GvHD therapies
- Anti-lymphocyte treatments
- Pharmacokinetic studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.